Developing new drugs is a difficult process. With the aid of artificial intelligence, Pharmaceutical scientist Xuhan Liu has developed methods that can help make drug design cheaper and faster. PhD defence on 15 February.

Oncode Investigator Mario van der Stelt and his colleagues have discovered a new potential drug that suppresses chemotherapy induced neuropathic pain.

Medical drugs are expensive to make and can have an adverse effect on the environment. Researchers Stefano Cucurachi and Justin Lian have developed a framework to help the healthcare system assess the economic and environmental sustainability of medical compounds.

How do you know if a drug will actually work? The Leiden-based spin-off Omivera is developing a new technology that could provide clearer answers. The young company received a seed investment from the investment fund UNIIQ to support its development.

Mini organs-on-chips allow us to study how diseases develop and how drugs work. Although the technology is not new, it is becoming increasingly advanced. PhD candidate Bart Kramer hopes it will eliminate animal testing in the future.

There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated production of 3D cardiac microtissues. This platform will allow large numbers of drugs to be tested quickly

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.

Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…

One in two people will be diagnosed with cancer. World Cancer Day on 4 February raises awareness of the impact of this devastating disease. Leiden University is conducting various studies aimed at preventing and controlling cancer. Below are just a few examples.

It’s vital that universities are able to recognise the signs of alcohol and drug misuse in students. Staff also have an important role to play in talking about substance use. ‘That one conversation can make a difference’, says Jitske Hoogervorst, an adviser at Brijder addiction treatment services.

The Leiden Academic Centre for Drug Research (LACDR) has received a €750,000 grant from ZonMw for QPharmNL. This is a continuing education programme that trains professionals in computational techniques in pharmacology for innovative drug development.

On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…

One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.

A Dutch consortium has received €6.7 million to accelerate the development of nanomedicines together with patients. Researchers from Leiden University play a key role in the project.

Sometimes an idea seems so logical and elegant at first glance, that you later wonder why no one thought of it before. Two researchers from LACDR have teamed up to develop a completely synthetic alternative to antibodies—one that mimics their size, shape and function, but which is cheaper, more stable,…

A breakthrough from the PhD research of medical chemist Elmer Maurits may help patients with autoimmune diseases and blood cancer in the future. But bringing a discovery from the lab to the clinic is not so easily done. Thanks to NWO's Venture Challenge, Maurits and his team will receive ten weeks of…

How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…

In dermatology, there should be a high level of multidisciplinary collaboration among institutes and specialists, Professor of Translational Dermatology, Robert Rissmann, will say in his inaugural lecture on 8 July. He is building an infrastructure that will put pre-clinical and clinical skin research…

Two Leiden researchers have been awarded ERC Proof of Concept grants. These grants, each worth EUR 150,000, will help the grantees in their efforts to bridge the gap from basic science to real-life applications

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.

Through its Demonstrator Projects, the Dutch Oncode Accelerator consortium provides grants for preclinical cancer therapy development. The first call for these projects is open until September 2025.

A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

RARE-NL, a new collaboration between university hospitals, hopes to find treatments for rare diseases. Professor Teun van Gelder is representing the LUMC in the initiative.

Bacteria carry countless hidden treasures in their DNA: fragments that could hold the key to new medicines. But how do you pick out the most promising ones from millions of options? ‘Look at the switches that turn genes on and off,’ says molecular biologist Gilles van Wezel.

Two consortia led by Leiden researchers have been awarded over one million euros by the Dutch Research Council and the Ministry of Health, Welfare and Sport to find solutions to antimicrobial resistance.

Leiden researcher Anne-Grete Märtson brought together a large number of studies to better understand antibiotic dosing in patients with obesity. The publication in a renowned medical journal has already garnered much positive reactions, Märtson says. ‘It’s high time researchers started sharing more…

For each university unit, the ICT Shared Service Centre (ISSC) has an appointed ICT contact person responsible for applying for ICT facilities for research, teaching and operational management.